George Buchman
Vice President, Pre-Clinical and Process Development • Catalent Cell and Gene Therapy
Buchman joined Catalent through its acquisition of Paragon Gene Therapy in 2019. He has more than 30 years of experience in the biotech industry and has held roles at companies including Life Technologies (now Thermo Fisher), Celera Genomics and GeneLogic. Dr. Buchman obtained a bachelor’s degree in biochemistry from Albright College, Reading, Pennsylvania, and a doctorate in biochemistry from University of Maryland.
Also Speaking
Eytan Abraham
Vice President & Business Head, Cell Therapy, Gene Therapy • Nucleic Acids
10 November 2022
Also Speaking
Investor List
Take a look at some of the investors who attended Advanced Therapies Week 2023.
6 January 2023
